C16 Biosciences logo

C16 Biosciences

Emerging

C16 Biosciences produces Palmless, a biofermentation-derived alternative to palm oil targeting the beauty, personal care, and food industries; raised $20M Series A led by Breakthrough Energy Ventures;

Best for: Sustainable Palm Oil Alternative via FermentationEmerging, rapid growth
Life Sciences & BioTechSustainable Palm Oil Alternative via FermentationWebsiteUpdated May 2026

Company Overview

About C16 Biosciences

C16 Biosciences is a biotechnology company founded in 2017 by David Heller, Irina Gerry, and Harry McNamara and headquartered in New York City. The company developed a proprietary biomanufacturing platform that uses engineered yeast fermentation to produce Palmless — a sustainable, palm oil-equivalent ingredient designed for beauty, personal care, and food applications. Palm oil is one of the most widely used commodity oils in the world, but its production is responsible for massive tropical deforestation, habitat destruction, and biodiversity loss, particularly in Indonesia and Malaysia. C16's fermentation approach produces oils with the same functional performance as palm oil — high saturation, solid at room temperature, neutral flavor — without any agricultural land conversion.

Business Model & Competitive Advantage

The company's technology leverages oleaginous yeast strains that naturally accumulate high levels of lipids during fermentation. C16 engineers these strains to produce specific fatty acid profiles that match the functional properties required by formulators in the cosmetics and food industries. The result is a drop-in ingredient that requires no reformulation, allowing brands to substitute conventional palm oil with Palmless while maintaining product performance. C16 raised a $20M Series A led by Breakthrough Energy Ventures — Bill Gates' climate investment fund — with participation from Prelude Ventures and other investors, reflecting the strong alignment between its mission and climate-focused capital.

Competitive Landscape 2025–2026

C16 Biosciences targets cosmetic ingredient suppliers, personal care brands, and food manufacturers seeking credible palm-free alternatives to meet sustainability commitments and consumer demand for ethical sourcing. The company's Palmless brand is positioned as a premium, certified sustainable ingredient with a transparent and traceable supply chain — a key differentiator in an industry where greenwashing claims around existing "sustainable palm oil" certifications (such as RSPO) remain controversial.

Founded
2017
Headquarters
New York City
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

C16 Biosciences is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.

Frequently Asked Questions

Similar Brands

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Compare C16 Biosciences with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For C16 Biosciences

Claim This Profile

Are you from C16 Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim C16 Biosciences Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention C16 Biosciences vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →